TY - JOUR
T1 - Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression
T2 - Results from the PREVENT study
AU - Thase, Michael E.
AU - Gelenberg, Alan
AU - Kornstein, Susan G.
AU - Kocsis, James H.
AU - Trivedi, Madhukar H.
AU - Ninan, Philip
AU - Li, Thomas
AU - Pedersen, Ron
AU - Keller, Martin
N1 - Funding Information:
This analysis was sponsored by Wyeth Research, Collegeville, Pennsylvania , which was acquired by Pfizer Inc. in October 2009. Wyeth Research had a role in the study design and the decision to submit this manuscript for publication.
Funding Information:
Dr. Trivedi has received research support from the Agency for Healthcare Research and Quality , Corcept Therapeutics , Cyberonics , Merck , the National Alliance for Research in Schizophrenia and Depression, the National Institute of Mental Health, the National Institute on Drug Abuse, Novartis, Pharmacia and Upjohn , Predix Pharmaceuticals (Epix) , Solvay , and Targacept . He has received consulting and speaker fees from Abbott, Abdi Ibrahim, Akzo (Organon Pharmaceuticals), AstraZeneca, Bristol-Myers Squibb, Cephalon, Evotec, Fabre Kramer Pharmaceuticals, Forest, GlaxoSmithKline, Janssen, Johnson & Johnson PRD, Eli Lilly, Meade Johnson, Medtronic, Neuronetics, Otsuka, Parke-Davis, Pfizer, Sepracor, Shire Development, VantagePoint, and Wyeth-Ayerst.
Funding Information:
Dr. Kornstein has received grants/research support from AstraZeneca , Bristol-Myers Squibb , Boehringer-Ingelheim , the Department of Health and Human Services , Eli Lilly , Forest , the National Institute of Mental Health, Novartis , Pfizer , Sepracor, Sanofi-Synthelabo , Takeda , and Wyeth . She has been on advisory boards for Bristol-Myers Squibb, Eli Lilly, Endo, Forest, Neurocrine, Pfizer, Sepracor, Takeda, and Wyeth, and receives book royalties from Guilford Press.
Funding Information:
Dr. Thase has been an advisor or consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, MedAvante, Neuronetics, Novartis, Schering-Plough, Shire, Supernus, Transcept, and Pfizer (formerly Wyeth Research). He has received grant support from Eli Lilly , GlaxoSmithKline , the National Institute of Mental Health , and Sepracor . Dr. Thase has been on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Pfizer (formerly Wyeth Research), and holds equity in MedAvante. Dr. Thase receives royalties from American Psychiatric Publishing, Guilford Publications, Herald House, and W.W. Norton and Company. His spouse is employed by Embryon, LLC, A Division of Advanced Health Media, LLC (formerly Medesta Publications Group, A Business of Advogent).
PY - 2011/3
Y1 - 2011/3
N2 - This secondary analysis from the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) study compared the efficacy of venlafaxine ER and fluoxetine for the prevention of recurrence in patients with a history of recurrent major depressive disorder (MDD). Patients received double-blind treatment with venlafaxine ER (75-300 mg/d) or fluoxetine (20-60 mg/d) for 10 weeks (acute phase). Responders (17-item Hamilton Rating Scale for Depression [HAM-D17] score ≤12 and ≥50% reduction from baseline) continued on the same treatment during the 6-month continuation phase. At the start of the first and second 12-month maintenance phases, venlafaxine ER responders were randomly assigned to receive venlafaxine ER or placebo, whereas patients receiving fluoxetine continued to receive fluoxetine throughout both maintenance phases. The primary outcome was time to recurrence (HAM-D17 > 12, reduction in HAM-D17 score ≤ 50% from acute baseline, and meeting DSM-IV criteria for a diagnosis of MDD), which was assessed using Kaplan-Meier estimates. Using the primary definition of recurrence, the estimated probability of not experiencing a recurrence was 71.9% for venlafaxine ER (n 160) and 55.8% for fluoxetine (n 99) across 24 months of maintenance treatment. For this primary analysis, the overall effect of venlafaxine ER treatment was not statistically significant (p 0.399) compared with fluoxetine; however, a significant treatment-by-time interaction was observed (p 0.034). No significant between-group differences were observed with any of the secondary efficacy variables. Venlafaxine ER and fluoxetine were similarly well tolerated across 2 years of maintenance-phase therapy.
AB - This secondary analysis from the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) study compared the efficacy of venlafaxine ER and fluoxetine for the prevention of recurrence in patients with a history of recurrent major depressive disorder (MDD). Patients received double-blind treatment with venlafaxine ER (75-300 mg/d) or fluoxetine (20-60 mg/d) for 10 weeks (acute phase). Responders (17-item Hamilton Rating Scale for Depression [HAM-D17] score ≤12 and ≥50% reduction from baseline) continued on the same treatment during the 6-month continuation phase. At the start of the first and second 12-month maintenance phases, venlafaxine ER responders were randomly assigned to receive venlafaxine ER or placebo, whereas patients receiving fluoxetine continued to receive fluoxetine throughout both maintenance phases. The primary outcome was time to recurrence (HAM-D17 > 12, reduction in HAM-D17 score ≤ 50% from acute baseline, and meeting DSM-IV criteria for a diagnosis of MDD), which was assessed using Kaplan-Meier estimates. Using the primary definition of recurrence, the estimated probability of not experiencing a recurrence was 71.9% for venlafaxine ER (n 160) and 55.8% for fluoxetine (n 99) across 24 months of maintenance treatment. For this primary analysis, the overall effect of venlafaxine ER treatment was not statistically significant (p 0.399) compared with fluoxetine; however, a significant treatment-by-time interaction was observed (p 0.034). No significant between-group differences were observed with any of the secondary efficacy variables. Venlafaxine ER and fluoxetine were similarly well tolerated across 2 years of maintenance-phase therapy.
KW - Fluoxetine
KW - Major depressive disorder
KW - PREVENT study
KW - Venlafaxine extended release
UR - http://www.scopus.com/inward/record.url?scp=79953846623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953846623&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychires.2010.07.009
DO - 10.1016/j.jpsychires.2010.07.009
M3 - Article
C2 - 20801464
AN - SCOPUS:79953846623
SN - 0022-3956
VL - 45
SP - 412
EP - 420
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
IS - 3
ER -